

# Question Paper

Exam Date & Time: 27-Nov-2017 (02:00 PM - 05:00 PM)



**MANIPAL UNIVERSITY**

**MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES  
END SEMESTER THEORY EXAMINATIONS - NOVEMBER 2017  
PROGRAM : MPHARM SEMESTER I**

**DATE : 27-11-2017**

**TIME : 2:00PM - 5:00PM**

*(Common Paper for the following specializations: Pharmaceutics, Industrial Pharmacy, Pharmaceutical Chemistry, Pharmaceutical Analysis, Pharmaceutical Quality Assurance, Pharmaceutical Biotechnology, Pharmacology and Pharmacognosy)*

**Modern Pharmaceutical Analytical Techniques [PQA-MQA101T]**

**Marks: 50**

**Duration: 180 mins.**

**a**

**Answer all the questions.**

**Answer the following (5 marks x 8 = 40 marks)**

- 1) Write a note on Ultra-Performance Liquid Chromatography. (5)
- 2) With the help of neat and labelled diagram, discuss the working of thermobalance employed in TGA. (5)
- 3) List the advantages ELISA and potentiometric titrations (5)
- 4) Explain the qualitative applications of UV/Visible spectroscopy in brief. (5)
- 5) Explain the working of Golay cell detector (5)
- 6) Explain the principle and applications of micellar electrokinetic chromatography (5)
- 7) Explain the information obtained from the proton NMR spectrum (5)
- 8) What are mass analyzers? Classify them with examples and explain any one (5)

**b**

**Answer the following with specific answers (2 marks x 5 = 10 marks)**

- 9) What is void volume and void time in HPLC? (2)
- A) (2)
- B) List the applications of X ray diffraction. (2)
- C) List the structural requirements for a molecule to exhibit fluorescence. (2)
- D) List the types of nebulizers used in AAS. (2)
- E) How simplification of complex proton NMR spectra can be achieved? (2)

# Paper

Time: 29-Nov-2017 (02:00 PM - 05:00 PM)



## MANIPAL UNIVERSITY

### MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES END SEMESTER THEORY EXAMINATIONS - NOVEMBER 2017 PROGRAM: MPHARM SEMESTER 1 DATE: 29/11/2017 TIME: 2:00PM - 5:00PM

#### Quality Management Systems [PQA-MQA102T]

Duration: 180 mins.

Marks: 50

Answer all the questions.

Answer the following (5 marks x 8 = 40 marks)

- 1) Write a note on stability testing of drug substance with special emphasis given to scope, selection of batches, testing frequency and storage conditions as per ICH Q1(A)R2. (5)
- 2) Write a note on statistical control charts based on variables. (5)
- 3) Write a note on risk assessment as per ICH Q9. (5)
- 4) Define the concept of regulatory compliance. Enlist the types and reasons for benchmarking in pharmaceutical industry. (5)
- 5) Discuss Total quality management system in detail. (5)
- 6) Write in detail about annual product review. (5)
- 7) Prepare a checklist for OOS investigation. (5)
- 8) Discuss CAPA in detail. (5)

Answer the following with specific answers (2 marks x 5 = 10 marks)

- 9) Differentiate between stress and accelerated stability testing. (2)
  - A) (2)
  - B) Define the terms "Risk" and "Quality Risk Management" as per ICH Q9. (2)
  - C) Give the significance of statistical process control. (2)
  - D) Define Six sigma concept. (2)
  - E) Give any four importance of CFR-21 part 11. (2)

-----End-----



**MANIPAL UNIVERSITY**

**MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES  
END SEMESTER THEORY EXAMINATIONS - NOVEMBER 2017  
PROGRAM : MPHARM SEMESTER I  
DATE : 01-12-2017  
TIME : 2:00PM - 5:00PM  
Quality Control and Quality Assurance [PQA-MQA103T]**

**Marks: 50**

**Duration: 180 mins.**

**Answer the following (5 marks x 8 = 40 marks)**

- 1) Discuss the responsibilities of study director and quality assurance unit in non-clinical testing facility as per Good Laboratory Practices (GLP). (5)
- 2) Discuss the building design and construction features of pharmaceutical plant as per cGMP guidelines. (5)
- 3) Classify impurities in new drug substance. Discuss the approach to develop the specification for the same as per the thresholds. (5)
- 4) Enlist and explain the IPQC test for tablets and capsules. (5)
- 5) Explain types of disposal methods for waste and scrap in pharmaceuticals. (5)
- 6) What is copyright? explain its types. (5)
- 7) Explain the content and structure of Standard operating procedure (5)
- 8) Explain in detail about Batch manufacturing record (5)

**Answer the following with specific answers (2 marks x 5 = 10 marks)**

- 9) Differentiate between Quality Assurance (QA) and Quality Control (QC). (2)
  - A) (2)
  - B) Enlist the types of trainings in pharmaceutical industry. (2)
  - C) Enlist the IPQC tests for parenterals. (2)
  - D) What are the objectives of IPQC test? (2)
  - E) Give two examples for level 2 and level 4 documents (2)

-----End-----

# on Paper

& Time: 04-Dec-2017 (02:00 PM - 05:00 PM)



## MANIPAL UNIVERSITY

**MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES**  
**END SEMESTER THEORY EXAMINATIONS - NOVEMBER 2017**  
**PROGRAM : MPHARM SEMESTER I**  
**DATE : 04-12-2017**  
**TIME : 2:00PM - 5:00PM**

### Product Development and Technology Transfer [PQA-MQA104T]

**Marks: 50**

**Duration: 180 mins.**

**Answer all the questions.**

**Answer the following (5 marks x 8 = 40 marks)**

- 1) What is pre-formulation? Why it is essential for drug development. (5)
- 2) What is solubility? Explain co-solvency and hydrotrophy with an example. (5)
- 3) Briefly discuss on Phase III clinical trials. (5)
- 4) What are the types of certifications under ANDA application? Write the procedure for ANDA application under paragraph IV certification. (5)
- 5) Briefly explain the BACPAC guidelines of USFDA. (5)
- 6) Discuss intra-cutaneous test for plastic containers for injectable preparation. (5)
- 7) Explain the responsibilities of receiving unit in technology transfer. (5)
- 8) Explain the documentation required in technology transfer in brief. (5)

**Answer the following with specific answers (2 marks x 5 = 10 marks)**

- 9) Why stability testing is essential? (2)
  - A)
  - B) What are the quality control tests for plastic containers for non-parenteral preparations. (2)
  - C) What is "sterilization test" and "fragmentation test" for the evaluation of rubber closures. (2)
  - D) What is a "phase IV clinical trial" as per USFDA? (2)
  - E) List the stages of formulation development in technology transfer. (2)

-----End-----